A new triazole, Bay R 3783, was compared with ketoconazole, itraconazole, and fluconazole, which were given via the alimentary tract at three dosages, and amphotericin B, which was given at 1 mg/kg intraperitoneally, in murine models of the systemic mycoses coccidioidomycosis, histoplasmosis, and blastomycosis. In a pulmonary coccidioidomycosis model, Bay R 3783, fluconazole, and itraconazole were essentially equally efficacious and more active than ketoconazole in protecting mice against death; but they were inferior to amphotericin B. In a short-term organ load experiment, Bay R 3783 and amphotericin B were equally effective and were more effective than the other drugs in reducing the amount of Coccidioides immitis in the lungs. Against meningocerebral coccidioidomycosis, Bay R 3783, itraconazole, and fluconazole at 25 mg/kg and amphotericin B prevented death only during therapy, with mortalities ensuing shortly thereafter. In mice with systemic histoplasmosis, Bay R 3783 and itraconazole at 25 mg/kg and amphotericin B prevented death in all mice through a 44-day observation period. Clearance of Histoplasma capsulatum from organs was similar in mice treated with Bay R 3783 and itraconazole; this clearance was greater than that in mice treated with ketoconazole and fluconazole but less than that in mice treated with amphotericin B. In mice with systemic blastomycosis, Bay R 3783 at 25 mg/kg yielded 90% survivors at 60 days, which was greater than that achieved with amphotericin B (60%) or itraconazole (30%). Clearance of Blastomyces dermatitidis from the lungs was greatest with Bay R 3783, followed by that with amphotericin B, itraconazole, fluconazole, and ketoconazole, in that order. Therefore, Bay R 3783 showed effectiveness comparable to or exceeding those of itraconazole and fluconazole and exceeding that of ketoconazole against these systemic mycoses in mice.
The chemotherapy of systemic infections caused by dimorphic fungi has relied on amphotericin B for three decades, and in recent years this polyene has been supplemented or supplanted by flucytosine and by the antifungal azoles. Whereas miconazole has found some utility by the parenteral, particularly intrathecal and intraventricular, routes (15) , other azoles (ketoconazole, itraconazole, and fluconazole) have the advantage of being effective even when given by the oral route. The newer triazoles itraconazole and fluconazole additionally appear to have the advantages of less toxicity and apparently greater potency than ketoconazole against some systemic pathogens and greater activity than ketoconazole against meningocerebral infections (1-5, 12, 13, 16, 17) .
Previous in vitro studies with Bay R 3783 and several other azoles against Coccidioides immitis (7) and fluconazole and ketoconazole against Histoplasma capsulatum (14) demonstrated the activity of this class of drug against the dimorphic fungal pathogens. This lead to the present study, in which Bay R 3783 ( Fig. 1) was evaluated in murine models of the systemic mycoses blastomycoses, coccidioidomycosis, and histoplasmosis. As described in this report, Bay R 3783 given by the oral route showed effectiveness comparable to or exceeding that of itraconazole or fluconazole.
MATERIALS AND METHODS
Drugs. Bay R 3783 was received as a powder from Bayer AG (Wuppertal, Federal Republic of Germany), fluconazole was received as a powder from Pfizer Inc. (Groton, Conn.), itraconazole was received as a powder from Janssen (Piscataway, N.J.), ketoconazole was purchased as Nizoral ( Bioassay. Mice were dosed with Bay R 3783 via oral gavage at 25 mg/kg and bled via cardiac puncture in groups of five mice each at intervals over a 24-h period. The bioassay with Candida pseudotropicalis was performed as described previously (2).
Statistical analyses. Results from short-term organ load experiments were analyzed by the Duncan multiple-range test, with significance determined at the P = 0.05 level. Survival data were analyzed by the Cox proportional hazards estimation by using one-sided tables in comparisons of control group with treatment group values and two-sided tables in comparisons of the Bay R 3783 group with other treatment group values. Significance was determined at the P = 0.05 level. Data inappropriate for Cox analysis were compared in a pair-wise fashion using the log-rank method, with significance determined at the P = 0.05 level. Analyses were made only for the groups treated with 25 mg of azole per ml and 1 mg of amphotericin B per ml for all experiments.
RESULTS
Susceptibility testing. Results of MIC testing with the parasitic phases of the fungal isolates and drugs used in this study are presented in Table 1 (results for C. immitis are, in part, from the previous report of Hector et al. [7] ).
Coccidioidomycosis. With the pulmonary model of coccidioidomycosis, three dosage levels of the four azoles were compared with a single dosage level of amphotericin B in animals infected with a large inoculum. At 2.5 mg/kg, none of the azoles was particularly effective, although the itraconazole-treated group had the best outcome (data not shown). At 10 mg/kg only ketoconazole was without effect, and itraconazole was superior to Bay R 3783 and fluconazole ( Fig. 2A) . Treatment with 25 mg of the azoles per kg and 1 mg of amphotericin B per kg resulted in a significant delay in deaths in comparison with controls for all drugs except ketoconazole (P = 0.06) (Fig. 2B) . Among the azoles, Bay R 3783 forestalled the onset of deaths the longest, but ultimately, the onset of death in mice treated with Bay R 3783 was not statistically different from that in the itraconazoleand fluconazole-treated groups. Only amphotericin B completely prevented deaths through day 60.
In pulmonary model in mice. Drugs were given for 5 days, and then the lungs were removed after a 48-h washout period for quantiiative cultures. Bay R 3783 and amphotericin B were statistically superior to the other azoles under the conditions that we used, effecting a 5-log-unit reduction in CFU (Table  2) . Ketoconazole w'as without effect at the doses we used, while itraconazole and fluconazole had a moderate degree of efficacy.
Histoplasmosis. In a survival experiment with the systemic model of histoplasmosis in mice infected intravenously with a highly lethal challenge of yeast-phase H. capsulatum G217B, three dose levels of the four azoles and amphotericin B at 1 mg/kg were compared. At 2.5 mg/kg, none of the azoles was able to prevent deaths completely, although the itraconazole-treated group had the best outcome (Fig. 4A) . At 10 mg/kg, only ketoconazole was without effect, with itraconazole being slightly superior to Bay R 3783 and fluconazole (Fig. 4B ). Itraconazole and Bay R 3783 at 25 mg/kg and amphotericin B at 1 mg/kg were able to prevent deaths completely through day 44 and were statistically superior to fluconazole, which was, in turn, statistically superior to ketoconazole (Fig. 4C) . All treatment groups were statistically different from the control group.
In a short-term organ load assay, the various treatments resulted in a broad range of responses in the groups of mice (Table 3 ). All drugs resulted in significant reductions in viable fungal cells in livers and spleens in comparison with those in controls, with amphotericin B being significantly more active than any of the azoles, followed by Bay R 3783, itraconazole, and ketoconazole and fluconazole, which were the least active under these conditions. Blastomycosis. Pulmonary blastomycosis was established by infecting the animals intravenously with the yeast phase of the causative organism, which established an infection with an acute course. Three dosage levels of azoles were compared with 1 mg of amphotericin B per kg in this model, with therapy being initiated after a 48-h delay and then given for 14 days. At 2.5 mg/kg, none of the azoles was able to prolong survival in comparison with that in controls. At 10 mg/kg, however, both itraconazole and Bay R 3783 showed a delay in the onset of mortalities until after the cessation of therapy (Fig. SA) , while fluconazole and ketoconazole were without obvious therapeutic effect. The experiment was continued for 60 days because there were discernible differences in the appearance between the mice that received 25 mg of itraconazole and Bay R 3783 per kg at the end of the first 30 days. Therapy with Bay R 3783 resulted in the fewest deaths by day 60 (Fig. SB) . This was statistically different (P = 0.11) from the results obtained with the other azoles but not those obtained with amphotericin B. Treatment with ketoconazole did not result in a significant response in comparison with that in the controls, but treatment with fluconazole resulted in a response that was statistically different (P = 0.03) from that of the control. A second experiment was initiated in which mice infected in a similar fashion were not treated until the first deaths occurred (day 6), at which time the azoles were administered at 25 mg/kg and amphotericin B was administered at 1 mg/kg for a total of 10 days. Interestingly, Bay R 3783 and amphotericin B appeared to be less effective than itraconazole initially, but all mice in the latter group ultimately died (Fig. 6) . Once again, the response to Bay R 3783 at 25 mg/kg was not statistically superior to that to amphotericin B at 1 mg/kg (P = 0.5) but was superior to that to itraconazole (P = 0.04). Treatment with either ketoconazole or fluconazole did not result in a significant delay in deaths.
A short-term organ load assay in which the four azoles and amphotericin B at 1 mg/kg were compared was conducted with the same model, with the lungs cultured as the target organ. Treatment with Bay R 3783 resulted in a statistically superior response to infection with B. dermatitidis compared with the response to all the other drugs (Table 4 ). This was followed by the responses of the amphotericin B-and itraconazole-treated groups (Table 4 ). The responses of the ketoconazole-and fluconazole-treated groups were indistinguishable from those of the untreated controls.
Bioassay. A limited study of the pharmacokinetics of Bay R 3783 at a dose of 25 mg/kg was performed. The data are presented in Fig. 7 In the experimental histoplasmosis model and Bay R 3783 were superior to the otho comparable to amphotericin B. The incompl the mice treated with fluconazole is in contra protection shown by Polak and Dixon (14) , wI azole at 10 mg/kg over a 20-day observation ever, the experimental conditions differed iI that Polak and Dixon (14) commenced ther infection of the mice, whereas in the present tion was not started until 48 h after infecti Dixon (14) observed that the reduction in CFI following treatment with fluconazole at 25 mg/ units compared with that following treatmen tericin B at 0.5 mg/kg; and at 50 mg/kg, flucor the viable count by 2 log units more than tha tericin B at 1.0 mg/kg. Previously, Kobayashi et al. (9, 10) found that 50% protective doses of fluconazole ranged from 6.2 to 47.3 mg/kg, varying with the strain of mouse and the size of the infective inoculum. In our experiments amphotericin B exceeded the effectiveness of fluconazole. In the present study the CFU per gram of liver regularly exceeded the count in the spleen, as Polak and Dixon (14) observed previously.
In the experimental blastomycosis model, 2 weeks of therapy with Bay R 3783 at 25 mg/kg was as effective as that with amphotericin B at 1 mg/kg in preventing deaths and was superior to itraconazole. The fact that Bay R 3783 excelled in the treatment of blastomycosis was also evident from its greater reduction in the number of viable organisms recovered from the lungs that was brought about by itraconazole 
